Restart Life Sciences Corp logo

Restart Life Sciences Corp

NEW
FRA:HN30 (Canada)  
€ 0.026 +0.0075 (+39.47%) Apr 17
Market Cap:
€ 689.00K ($ 791.00K)
Enterprise V:
€ 568.00K ($ 652.00K)
Volume:
-
Avg Vol (2M):
795.00
Trade In:
What is a stock summary page? Click here for an overview.

Business Description

Description
Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. It is focus is on creating health foods that address the needs of this community. Its Flagship developments includes Autism Spectrum, Health-Related Foods, Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA).

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 2.13
Equity-to-Asset -1.57
Debt-to-Equity -0.27
Debt-to-EBITDA -0.12
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 46.2
3-Year EPS without NRI Growth Rate 43.2
3-Year FCF Growth Rate 71.6

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 58.15
9-Day RSI 45.41
14-Day RSI 44.1
3-1 Month Momentum % 79.17
6-1 Month Momentum % 760
12-1 Month Momentum % -14

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.37
Quick Ratio 0.37
Cash Ratio 0.35

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -17.3

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % 2353.57
Net Margin % -53.57
FCF Margin % 252.63
ROE % Neg. Equity
ROA % 13.56
ROIC % -1049.36
3-Year ROIIC % -493.49
ROC (Joel Greenblatt) % -6460.78
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio 4.29
EV-to-EBIT -1.51
EV-to-EBITDA -1.52
EV-to-Revenue -35.64
EV-to-FCF -14.06
Earnings Yield (Greenblatt) % -66.23
FCF Yield % -6.53

Financials

FRA:HN30's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Restart Life Sciences Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) -0.019
EPS (TTM) (€) 0.009
Beta 12.58
3-Year Sharpe Ratio 0.79
3-Year Sortino Ratio 4.64
Volatility % 672.11
14-Day RSI 44.1
14-Day ATR (€) 0.00518
20-Day SMA (€) 0.032175
12-1 Month Momentum % -14
52-Week Range (€) 0.0002 - 0.099
Shares Outstanding (Mil) 18.13

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Restart Life Sciences Corp Filings

Filing Date Document Date Form
No Filing Data

Restart Life Sciences Corp Stock Events

Financials Calendars
Event Date Price (€)
No Event Data

Restart Life Sciences Corp Frequently Asked Questions

What is Restart Life Sciences Corp(FRA:HN30)'s stock price today?
The current price of FRA:HN30 is €0.03. The 52 week high of FRA:HN30 is €0.10 and 52 week low is €0.00.
When is next earnings date of Restart Life Sciences Corp(FRA:HN30)?
The next earnings date of Restart Life Sciences Corp(FRA:HN30) is .
Does Restart Life Sciences Corp(FRA:HN30) pay dividends? If so, how much?
Restart Life Sciences Corp(FRA:HN30) does not pay dividend.

Press Release

Subject Date
No Press Release